Kawakami Y, Rosenberg S A
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1502, USA.
Immunol Res. 1997;16(4):313-39. doi: 10.1007/BF02786397.
T-cells play an important role in in vivo tumor rejection in many animal tumor models and in human melanoma. Many human tumor antigens recognized by autologous T-cells have now been identified. These are found to be nonmutated and mutated peptides derived from various self proteins as well as viral proteins. A variety of mechanisms involved in generating these T-cell epitopes on growing cancers have also been identified. However, the role of these identified antigens remains to be evaluated. Passive or active immunotherapies using these identified tumor antigens are being conducted in many institutions. The results obtained from these clinical trials may give us better insight into the role of T-cell responses to each antigen in tumor rejection as well as the development of new antigen-specific immunotherapies for patients with cancer.
在许多动物肿瘤模型和人类黑色素瘤中，T细胞在体内肿瘤排斥反应中发挥着重要作用。目前已鉴定出许多可被自体T细胞识别的人类肿瘤抗原。这些抗原被发现是源自各种自身蛋白以及病毒蛋白的未突变和突变肽段。在生长的癌症上产生这些T细胞表位所涉及的多种机制也已被确定。然而，这些已鉴定抗原的作用仍有待评估。许多机构正在开展使用这些已鉴定肿瘤抗原的被动或主动免疫疗法。从这些临床试验中获得的结果可能会让我们更好地了解T细胞对每种抗原的反应在肿瘤排斥中的作用，以及为癌症患者开发新的抗原特异性免疫疗法。
